Cancer Biotech Lixte Abandons Drug Identity to Acquire Battery Storage Company
Strategic Pivot
Company Background
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company whose principal asset is LB-100, a first-in-class PP2A inhibitor it describes as well-tolerated in cancer patients at doses associated with anti-cancer activity. Proof-of-concept trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. A wholly owned subsidiary, Liora Technologies Europe Ltd., is also developing electronically controlled proton therapy systems under the LiGHT System brand.
The company trades on the Nasdaq Capital Market under the ticker LIXT, with a market cap of approximately $132 million. No financial deterioration or going-concern language appears in the filings reviewed; the strategic shift appears to be a deliberate decision by management rather than a response to an acute financial crisis.
NOMAD Transportable Power Systems, the acquisition target, describes itself as the market leader in deployable, utility-grade battery energy storage systems (BESS) and claims to be the first company to bring a mobile, utility-grade 1 MW BESS to market. According to the press release accompanying the merger announcement, NOMAD's revenue grew approximately 175% year-over-year in 2025, with management projecting further growth of approximately 135% in 2026.
What Was Disclosed
A $6.5 million secured promissory note, issued by Lixte to NOMAD on June 17, 2026 — six days after the merger agreement was signed — is secured by a first-priority security interest in substantially all of NOMAD's assets. The note's proceeds serve two purposes: first, to repay in full NOMAD's outstanding obligations under a Loan and Security Agreement dated February 12, 2024, between NOMAD and BPCP Investment Holdings, LP (successor in interest to Bay Point Capital Partners II, LP), with that portion disbursed directly to BPCP by Lixte on NOMAD's behalf; and second, for NOMAD's working capital and general corporate purposes.